Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib vs Sorafenib + HAIC in Advanced HCC with PVTT
NCT02774187Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- May 2016
- Primary completion
- Jul 2017
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 6 months. Started May 2016; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02774187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02774187.